Literature DB >> 29937981

Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis.

Joseph B Sweeney1, Marcus Rattray2, Victoria Pugh2,3, Lucy A Powell4.   

Abstract

Despite intense attention from biomedical and chemical researchers, there are few approved treatments for amyotrophic lateral sclerosis (ALS), with only riluzole (Rilutek) and edaravone (Radicava) currently available to patients. Moreover, the mechanistic basis of the activity of these drugs is currently not well-defined, limiting the ability to design new medicines for ALS. This Letter describes the synthesis of triazole-containing riluzole analogues, and their testing in a novel neuroprotective assay. Seven compounds were identified as having neuroprotective activity, with two compounds having similar activity to riluzole.

Entities:  

Year:  2018        PMID： 29937981      PMCID： PMC6004570          DOI： 10.1021/acsmedchemlett.8b00103

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  18 in total

1.  Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function.

Authors:  Y He; A Benz; T Fu; M Wang; D F Covey; C F Zorumski; S Mennerick
Journal:  Neuropharmacology       Date:  2002-02       Impact factor: 5.250

2.  Treatment of amyotrophic lateral sclerosis: lessons learned from many failures.

Authors:  P Hande Ozdinler; Richard B Silverman
Journal:  ACS Med Chem Lett       Date:  2014-10-08       Impact factor: 4.345

3.  Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines.

Authors:  P Jimonet; F Audiau; M Barreau; J C Blanchard; A Boireau; Y Bour; M A Coléno; A Doble; G Doerflinger; C D Huu; M H Donat; J M Duchesne; P Ganil; C Guérémy; E Honor; B Just; R Kerphirique; S Gontier; P Hubert; P M Laduron; J Le Blevec; M Meunier; J M Miquet; C Nemecek; S Mignani
Journal:  J Med Chem       Date:  1999-07-29       Impact factor: 7.446

4.  2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties.

Authors:  J Benavides; J C Camelin; N Mitrani; F Flamand; A Uzan; J J Legrand; C Gueremy; G Le Fur
Journal:  Neuropharmacology       Date:  1985-11       Impact factor: 5.250

5.  Motor neurons are rich in non-phosphorylated neurofilaments: cross-species comparison and alterations in ALS.

Authors:  Y M Tsang; F Chiong; D Kuznetsov; E Kasarskis; C Geula
Journal:  Brain Res       Date:  2000-04-07       Impact factor: 3.252

6.  Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study.

Authors:  A Alonso; G Logroscino; S S Jick; M A Hernán
Journal:  Eur J Neurol       Date:  2009-06       Impact factor: 6.089

7.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

Authors:  D R Rosen; T Siddique; D Patterson; D A Figlewicz; P Sapp; A Hentati; D Donaldson; J Goto; J P O'Regan; H X Deng
Journal:  Nature       Date:  1993-03-04       Impact factor: 49.962

8.  Motor neuron disease in 2017: Progress towards therapy in motor neuron disease.

Authors:  Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2018-01-19       Impact factor: 42.937

Review 9.  Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS).

Authors:  Timur A Mavlyutov; Lian-Wang Guo; Miles L Epstein; Arnold E Ruoho
Journal:  J Pharmacol Sci       Date:  2015-01-05       Impact factor: 3.337

10.  Assessing social isolation in motor neurone disease: a Rasch analysis of the MND Social Withdrawal Scale.

Authors:  Chris J Gibbons; Everard W Thornton; John Ealing; Pamela J Shaw; Kevin Talbot; Alan Tennant; Carolyn A Young
Journal:  J Neurol Sci       Date:  2013-08-09       Impact factor: 3.181
View more
  4 in total

Review 1.  From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies.

Authors:  Serge Mignani; Jean-Pierre Majoral; Jean-François Desaphy; Giovanni Lentini
Journal:  Molecules       Date:  2020-07-22       Impact factor: 4.411

Review 2.  1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview.

Authors:  Khurshed Bozorov; Jiangyu Zhao; Haji A Aisa
Journal:  Bioorg Med Chem       Date:  2019-07-04       Impact factor: 3.641

3.  DMSO-mediated palladium-catalyzed cyclization of two isothiocyanates via C-H sulfurization: a new route to 2-aminobenzothiazoles.

Authors:  Guangkai Yao; Bing-Feng Wang; Shuai Yang; Zhi-Xiang Zhang; Han-Hong Xu; Ri-Yuan Tang
Journal:  RSC Adv       Date:  2019-01-25       Impact factor: 3.361

4.  Riluzole-Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis.

Authors:  Claudia Albertini; Alessandra Salerno; Silvia Atzeni; Elisa Uliassi; Francesca Massenzio; Annalisa Maruca; Roberta Rocca; Marko Mecava; Filomena S G Silva; Débora Mena; Pedro Valente; Ana I Duarte; Daniel Chavarria; Maicol Bissaro; Stefano Moro; Stephanie Federico; Giampiero Spalluto; Ondřej Soukup; Fernanda Borges; Stefano Alcaro; Barbara Monti; Paulo J Oliveira; Josè C Menéndez; Maria Laura Bolognesi
Journal:  ACS Chem Neurosci       Date:  2022-07-22       Impact factor: 5.780
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.